Syncope, Near Syncope, or Nonmechanical Falls as a Presenting Feature of COVID-19.

To the Editor:

Coronavirus disease 2019 (COVID-19) usually presents as a febrile illness with lower respiratory tract symptoms.1, 2, 3 However, atypical presentations, such as syncope, may occur. Annually in the United States, syncope triggers an estimated 1.2 million visits to emergency departments and 440,000 hospital admissions at a cost of $2.4 billion. Furthermore, there is wide variation among practitioners’ approaches to the evaluation of syncope, and in greater than half of the cases, the cause remains undetermined. The emergence of SARS-COV-2 may further complicate the evaluation of syncope. A missed or delayed diagnosis of COVID-19 because of an unusual presentation would lead to preventable exposures and increased transmission.

We sought to minimize missed or delayed diagnosis of COVID-19 by maintaining vigilance for atypical presentations of the disease.

Rochester Regional Health System is a 5-hospital health care system comprising 1,056 licensed beds, with an 11-county service area in upstate New York. For public health, infection control, and exposure determinations, the medical record of every patient who tests positive for SARS-CoV-2 by reverse-transcription polymerase chain reaction is prospectively reviewed. Statistical analysis was performed with ANOVA and χ2 tests.

As of March 31, 2020, of 1,950 patients tested, 163 have been confirmed as having a positive test result. After review of the first 102 consecutive patients, we observed that the main reason 24 (24%) initially sought care was syncope, near syncope, or a nonmechanical fall. Fever or the typical respiratory symptoms were secondarily or incidentally found. Compared with the group of patients who did not present with syncope, near syncope, or nonmechanical fall, a higher proportion of the syncope patients required oxygen, had gastrointestinal symptoms, or had elevated troponin levels. However, these differences were not significant (Table ). Furthermore, intravascular volume status, as reflected by mean blood urea nitrogen levels, was not significantly different (Figure ).

Table

Characteristics of COVID-19 patients with and without syncope.

	COVID-19 Patients With Syncope, Presyncope, and Nonmechanical Falls, 24/102 (23.5%) (Mean Age 61 Years)	COVID-19 Patients Without Syncope, Presyncope, and Nonmechanical Falls, 78/102 (76.5%) (Mean Age 57 Years)	P Value
Cardiovascular disease history (%)	7 (29)	22 (28)	.93
Required supplemental oxygen (%)	15 (62.5)	32 (41)	.06
Reported GI symptoms (%)	13 (54)	28 (36)	.11
Mean BUN	20.21	21.29	.76
Mean troponin level	0.40	0.74	.69
Patients with elevated troponin level (%)	6 (25)	9 (11.5)	.10

GI, Gastrointestinal; BUN, blood urea nitrogen.

Figure

One-way ANOVA comparing mean blood urea nitrogen values. CI, Confidence interval.

Numerous underlying conditions, both cardiogenic and noncardiogenic, can cause syncope or near syncope. Similarly, the reasons for syncope in COVID-19 patients are likely multifactorial. COVID-19 patients with underlying cardiovascular disease have increased mortality, and whether syncope is a manifestation of COVID-19–related cardiovascular disease is unknown. Cardiovascular disease is accompanied by dysregulation of angiotensin-converting enzyme 2, and SARS-Co-V2 uses the same enzyme to initiate infection.

Studies to date have not specifically noted syncope as a presenting symptom.1, 2, 3 However, in 3 reports from China, 7.3% of COVID-19 patients complained of heart palpitations, 2% complained of chest pain, and 9.4% complained of dizziness.1, 2, 3 However, those data may not be fully generalizable to US populations because of differences in the prevalence of tobacco use and cardiovascular disease, and because of dietary patterns.

We present this to alert clinicians that syncope may be a presenting feature of COVID-19 in the United States. Vigilance for syncope as a presenting symptom can potentially allow earlier identification and isolation of infected patients.